Related Experiment Video

Updated: Jun 6, 2026

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition
06:12

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition

Published on: March 3, 2023

A therapeutic target for smoking-associated lung cancer

Nicholas C Turner1, Michael J Seckl

  • 1Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK. nicholas.turner@icr.ac.uk

Science Translational Medicine
|December 17, 2010
PubMed

Insights

Amplification of the FGFR1 gene is a key driver in squamous cell lung cancer. This finding offers a potential new therapeutic target for lung cancer linked to smoking.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Squamous cell lung cancer (SCC) is a major cause of cancer-related mortality.
  • Identifying specific genetic drivers is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role of fibroblast growth factor receptor 1 (FGFR1) gene amplification in squamous cell lung cancer.
  • To determine if FGFR1 amplification represents a potential therapeutic target in smoking-associated lung cancer.

Main Methods:

  • Analysis of genetic alterations in patient tumor samples.
  • Correlation of FGFR1 gene amplification with clinical outcomes.

Main Results:

  • FGFR1 gene amplification was identified as a significant oncogenic aberration in squamous cell lung cancer.
  • This genetic variation occurs at a relatively high frequency in this cancer type.

Conclusions:

  • FGFR1 amplification is a major driver of squamous cell lung cancer.
  • This aberration may serve as the first high-frequency therapeutic target for smoking-associated lung cancer.

More Related Videos

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations09:25

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations

Published on: January 10, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...